FIG5. In vitro, TGF-β1 treated HNECs increased MG53/TGF-β1,
Col-a1 and ZO-1, on the contrary, TGF-β1 inhibitor treated decreased
MG53/TGF-β1, Col-a1 and ZO-1
A. In vitro, TGF-β1(10ng/ml) or/and inhibitor TGF-β1(50nM) treatment
HNECs of Control、CRSsNP and CRSwNP for 72h, the expression of
MG53/TGF-β1/Smad/ Col-a1 /ZO-1 by Western blot. B. The expressions of
MG53/TGF- β1/Smad/ Col-a1 /ZO-1 in treatment by TGF-β1 or/and inhibitor
TGF-β1 of nasal epithelial cells of CRSwNP were analyzed by Western
blot. C. The expressions of MG53/TGF- β1/Smad/ Col-a1 /ZO-1 in treatment
by TGF-β1 or inhibitor TGF-β1 of epithelial cells of the nasal mucosa of
CRSwNP were analyzed by RT-qPCR. D. Immunofluorescence was used to
detect ZO-1 expression in CRSwNP treated with TGF-β1/inhibitor
TGFβ1/Ad-MG53(Cells were treated by TGF-β1/inhibitor TGFβ1/ Ad-MG53 for
72h).
Error bars are shown as means ±SEMs. Significance was calculated by
using the unpaired Student t test (FIG5 E). Significance was calculated
by using the paired Student t test (FIG2 C and D). *p<0.05
and**p<0.01. ns not Significant.